Compare Stocks: RNXT, TMCI, TLSI, and STIM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
RNXT RenovoRx	$1.69 -2.3%	$1.37	$0.70 ▼ $2.59	$76.27M	1.12	1.49 million shs	566,763 shs
STIM Neuronetics	$2.90 -2.4%	$2.55	$0.80 ▼ $3.44	$220.97M	1.16	1.26 million shs	1.12 million shs
TLSI TriSalus Life Sciences	$5.10 +4.1%	$4.84	$2.20 ▼ $7.95	$314.03M	0.44	106,115 shs	606,910 shs
TMCI Treace Medical Concepts	$4.49 -0.9%	$4.50	$1.17 ▼ $7.30	$292.01M	1.4	230,160 shs	343,740 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
RNXT RenovoRx	0.00%	-3.98%	+28.03%	+83.70%	+38.52%
STIM Neuronetics	0.00%	-4.29%	-6.15%	+135.77%	+1.75%
TLSI TriSalus Life Sciences	0.00%	+9.44%	-2.49%	+25.00%	+6.25%
TMCI Treace Medical Concepts	0.00%	-0.44%	+0.67%	+7.16%	-36.22%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
RNXT RenovoRx	$1.69 -2.3%	$1.37	$0.70 ▼ $2.59	$76.27M	1.12	1.49 million shs	566,763 shs
STIM Neuronetics	$2.90 -2.4%	$2.55	$0.80 ▼ $3.44	$220.97M	1.16	1.26 million shs	1.12 million shs
TLSI TriSalus Life Sciences	$5.10 +4.1%	$4.84	$2.20 ▼ $7.95	$314.03M	0.44	106,115 shs	606,910 shs
TMCI Treace Medical Concepts	$4.49 -0.9%	$4.50	$1.17 ▼ $7.30	$292.01M	1.4	230,160 shs	343,740 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
RNXT RenovoRx	0.00%	-3.98%	+28.03%	+83.70%	+38.52%
STIM Neuronetics	0.00%	-4.29%	-6.15%	+135.77%	+1.75%
TLSI TriSalus Life Sciences	0.00%	+9.44%	-2.49%	+25.00%	+6.25%
TMCI Treace Medical Concepts	0.00%	-0.44%	+0.67%	+7.16%	-36.22%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
RNXT RenovoRx	2.75	Moderate Buy	$8.50	402.96% Upside
STIM Neuronetics	2.67	Moderate Buy	$4.67	60.92% Upside
TLSI TriSalus Life Sciences	2.40	Hold	$8.67	69.93% Upside
TMCI Treace Medical Concepts	1.86	Reduce	$5.17	15.14% Upside

Current Analyst Ratings Breakdown

Latest RNXT, TMCI, TLSI, and STIM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	STIM Neuronetics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$6.00
9/14/2026	STIM Neuronetics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/11/2026	STIM Neuronetics	B Riley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
9/11/2026	STIM Neuronetics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$5.00
9/10/2026	TLSI TriSalus Life Sciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
9/9/2026	TLSI TriSalus Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
9/9/2026	STIM Neuronetics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$6.00
9/9/2026	TLSI TriSalus Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
9/2/2026	RNXT RenovoRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/31/2026	TMCI Treace Medical Concepts	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/18/2026	RNXT RenovoRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
RNXT RenovoRx	$1.12M	68.10	N/A	N/A	$0.15 per share	11.27
STIM Neuronetics	$149.16M	1.48	N/A	N/A	$0.38 per share	7.63
TLSI TriSalus Life Sciences	$45.15M	6.96	N/A	N/A	($0.68) per share	-7.50
TMCI Treace Medical Concepts	$212.69M	1.37	N/A	N/A	$1.37 per share	3.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
RNXT RenovoRx	-$11.17M	-$0.31	N/A	N/A	N/A	-621.71%	-135.11%	-101.91%	11/12/2026 (Estimated)
STIM Neuronetics	-$39M	-$0.44	N/A	N/A	N/A	-19.62%	-125.11%	-22.15%	11/3/2026 (Estimated)
TLSI TriSalus Life Sciences	-$39.23M	-$1.30	N/A	N/A	N/A	-62.59%	N/A	-64.47%	11/12/2026 (Estimated)
TMCI Treace Medical Concepts	-$59M	-$0.93	N/A	N/A	N/A	-28.99%	-71.37%	-30.49%	11/5/2026 (Estimated)

Latest RNXT, TMCI, TLSI, and STIM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	RNXT RenovoRx	-$0.0725	-$0.05	+$0.0225	-$0.06	$0.70 million	$0.91 million
8/11/2026	Q2 2026	STIM Neuronetics	-$0.1230	-$0.05	+$0.0730	-$0.05	$40.17 million	$41.57 million
8/7/2026	Q2 2026	TMCI Treace Medical Concepts	-$0.2980	-$0.24	+$0.0580	-$0.24	$44.02 million	$45.38 million
8/6/2026	Q2 2026	TLSI TriSalus Life Sciences	-$0.1550	-$0.16	-$0.0050	-$0.16	$10.27 million	$11.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
RNXT RenovoRx	N/A	N/A	N/A	N/A	N/A
STIM Neuronetics	N/A	N/A	N/A	N/A	N/A
TLSI TriSalus Life Sciences	N/A	N/A	N/A	N/A	N/A
TMCI Treace Medical Concepts	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
RNXT RenovoRx	N/A	5.74	5.53
STIM Neuronetics	2.84	1.88	1.69
TLSI TriSalus Life Sciences	5.05	5.35	4.97
TMCI Treace Medical Concepts	0.83	2.90	1.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
RNXT RenovoRx	3.10%
STIM Neuronetics	53.59%
TLSI TriSalus Life Sciences	2.58%
TMCI Treace Medical Concepts	84.08%

Insider Ownership

Company	Insider Ownership
RNXT RenovoRx	9.40%
STIM Neuronetics	8.40%
TLSI TriSalus Life Sciences	16.30%
TMCI Treace Medical Concepts	23.42%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
RNXT RenovoRx	17	45.13 million	40.89 million	Not Optionable
STIM Neuronetics	658	76.20 million	69.80 million	Optionable
TLSI TriSalus Life Sciences	102	61.58 million	51.54 million	Not Optionable
TMCI Treace Medical Concepts	450	65.04 million	49.80 million	Optionable

RNXT, TMCI, TLSI, and STIM Headlines

Recent News About These Companies

Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D(R) Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty(R) Procedure

September 18 at 10:39 PM | marketscreener.comM

Treace Medical Concepts, Inc.: Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D Study Demonstrating Sustained, Positive Outcomes of the ...

September 18 at 7:20 AM | finanznachrichten.de

Treace Medical Concepts Presents 5-Year ALIGN3D, 2-Year MTA3D and SPRINT Clinical Study Results at AOFAS Annual Meeting

September 17 at 5:31 PM | quiverquant.comQ

Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure

September 17 at 5:16 PM | globenewswire.com

Treace Highlights Foot & Ankle Portfolio Updates At 2026 AOFAS Annual Meeting

September 16, 2026 | rttnews.com

Treace Medical Concepts to Showcase New Foot and Ankle Innovations and Clinical Data at AOFAS 2026

September 15, 2026 | quiverquant.comQ

Treace Highlights Product Innovations and Clinical Data Across its Expanding Foot & Ankle Portfolio at the 2026 AOFAS Annual Meeting

September 15, 2026 | globenewswire.com

NexGel (NASDAQ:NXGL) vs. Treace Medical Concepts (NASDAQ:TMCI) Head-To-Head Survey

September 12, 2026 | americanbankingnews.com

BlackRock Inc. Takes Position in Treace Medical Concepts, Inc. $TMCI

September 6, 2026 | marketbeat.com

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Given Consensus Recommendation of "Reduce" by Analysts

September 5, 2026 | marketbeat.com

Bank of America Corp DE Has $4.31 Million Stock Holdings in Treace Medical Concepts, Inc. $TMCI

August 29, 2026 | marketbeat.com

Treace Medical Concepts (NASDAQ:TMCI) CEO John Treace Buys 5,000 Shares

August 25, 2026 | insidertrades.com

John Treace Acquires 5,000 Shares of Treace Medical Concepts (NASDAQ:TMCI) Stock

August 24, 2026 | marketbeat.com

Insider Buying: Treace Medical Concepts (NASDAQ:TMCI) CEO Acquires 11,000 Shares

August 24, 2026 | marketbeat.com

Treace Medical Concepts (NASDAQ:TMCI) CEO John Treace Acquires 39,944 Shares of Stock

August 24, 2026 | marketbeat.com

Weber Capital Management LLC ADV Takes $2.35 Billion Position in Treace Medical Concepts, Inc. $TMCI

August 24, 2026 | marketbeat.com

Treace Medical Concepts Earnings Call Signals Cautious Rebound

August 18, 2026 | tipranks.com

Treace Medical (TMCI) Q2 2026 Earnings Call Transcript

August 14, 2026 | finance.yahoo.com

Treace Medical Concepts, Inc. Q2 2026 Earnings Call Summary

August 8, 2026 | finance.yahoo.com

Treace Medical Concepts: Q2 Earnings Snapshot

August 7, 2026 | seattlepi.comS

Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNXT, TMCI, TLSI, and STIM Company Descriptions

RenovoRx NASDAQ:RNXT

$1.69 -0.04 (-2.31%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.69 0.00 (-0.18%)

As of 09/18/2026 07:56 PM Eastern

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Neuronetics NASDAQ:STIM

$2.90 -0.07 (-2.36%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.89 -0.01 (-0.45%)

As of 09/18/2026 07:55 PM Eastern

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

TriSalus Life Sciences NASDAQ:TLSI

$5.10 +0.20 (+4.08%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$5.12 +0.02 (+0.29%)

As of 09/18/2026 07:05 PM Eastern

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

Treace Medical Concepts NASDAQ:TMCI

$4.49 -0.04 (-0.88%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$4.56 +0.07 (+1.56%)

As of 09/18/2026 07:30 PM Eastern

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNXT, TMCI, TLSI, and STIM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNXT, TMCI, TLSI, and STIM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNXT, TMCI, TLSI, and STIM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNXT, TMCI, TLSI, and STIM Company Descriptions

RenovoRx NASDAQ:RNXT

Neuronetics NASDAQ:STIM

TriSalus Life Sciences NASDAQ:TLSI

Treace Medical Concepts NASDAQ:TMCI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNXT, TMCI, TLSI, and STIM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNXT, TMCI, TLSI, and STIM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNXT, TMCI, TLSI, and STIM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNXT, TMCI, TLSI, and STIM Company Descriptions

RenovoRx NASDAQ:RNXT

Neuronetics NASDAQ:STIM

TriSalus Life Sciences NASDAQ:TLSI

Treace Medical Concepts NASDAQ:TMCI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools